Rizatriptan |
Maxalt |
Maxalt-Mlt |
MK-462 |
MK 462 FREE BASE |
RIZATRIPTANUM |
BIDD:GT0361 |
RIZATRIPTAN (INN) |
MOLPORT-003-666-600 |
AC1L1JK9 |
1H-INDOLE-3-ETHANAMINE, N,N-DIMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)- |
N,N-DIMETHYL-2-[5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]-ETHANAMINE |
UNII-51086HBW8G |
RIZATRIPTAN BENZOAT |
5078 |
144034-80-0 |
CHEBI:48273 |
N,N-DIMETHYL-2-[5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]ETHANAMINE |
LS-83053 |
SPECTRUM1505189 |
NCGC00095899-01 |
TL8000966 |
DB00953 |
AC-1712 |
RISATRIPTAN |
N,N-DIMETHYL-2-[5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]ETHYLAMINE |
7854588 |
L000812 |
C093622 |
N,N-DIMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOLE-3-ETHANAMINE |
D08485 |
N,N-DIMETHYL-2-[5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]ETHANAMINE |
145202-66-0 |
RIZATRIPTAN [INN:BAN] |
DAP000220 |
CID5078 |
I06-2272 |
Van-rizatriptan ODT |
Van-rizatriptan |
Teva-rizatriptan ODT |
Teva-rizatriptan |
Sandoz Rizatriptan ODT |
Rizatriptan Rdt |
Rizatriptan ODT |
Rizaport |
Riva-rizatriptan ODT |
Q-rizatriptan ODT |
PMS-rizatriptan Rdt |
Nat-rizatriptan ODT |
Nat-rizatriptan |
Mylan-rizatriptan ODT |
Mylan-rizatriptan |
Mint-rizatriptan ODT |
Maxalt Rpd |
Maxalt MLT |
Mar-rizatriptan |
Jamp-rizatriptan Ir |
Jamp-rizatriptan |
Ipg-rizatriptan |
Dom-rizatriptan Rdt |
Auro-rizatriptan ODT |
Auro-rizatriptan |
Apo-rizatriptan Rpd |
Apo-rizatriptan |
Act Rizatriptan ODT |
Act Rizatriptan |
178101771 |
FAS LIGAND |
FASLG |
DIMETHYL-[2-(5-[1,2,4]TRIAZOL-1-YLMETHYL-1H-INDOL-3-YL)-ETHYL]-AMINE |
Q-201675 |
3B2-6282 |
A808161 |
AB00698277-07 |
AB00698277-05 |
S-5530 |
CAS-144034-80-0 |
4CH-007687 |
ST2409343 |
KB-300182 |
SMR000469172 |
SC-17974 |
LP074528 |
DR000842 |
BR-72890 |
BC201784 |
AK-72890 |
AJ-08257 |
NCGC00095899-04 |
RL01798 |
AN-5270 |
AKOS015896596 |
FC0031 |
BDBM50033437 |
TOX21_111534 |
ZINC5895 |
IND062 |
MLS006010229 |
CC-317 |
SCHEMBL26662 |
DSSTOX_GSID_23565 |
DSSTOX_RID_77082 |
GTPL51 |
DSSTOX_CID_3565 |
PUBCHEM16714 |
RIZATRIPTAN; |
MAXALTREG |
MK-A462 |
DIMETHYL({2-[5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]ETHYL})AMINE |
ULFRLSNUDGIQQP-UHFFFAOYSA-N |
2-(5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-1H-INDOL-3-YL)-N,N-DIMETHYLETHANAMINE |
51086HBW8G |
135650905 |
51 |
C1538 |
FAS-LIGAND |
Drug Class | anti-migraine agents |
Year of Approval | 1998 |
Drug Categories | serotonin receptor agonists |
Drug Categories | serotonin modulators |
Drug Categories | serotonin agents |
Drug Categories | serotonin 5-ht1 receptor agonists |
Drug Categories | selective serotonin (5ht1) agonists |
Drug Categories | physiological effects of drugs |
Drug Categories | pharmacologic actions |
Drug Categories | organic chemicals |
Drug Categories | neurotransmitter agents |
Drug Categories | nervous system |
Drug Categories | molecular mechanisms of pharmacological action |
Drug Categories | migraine disorders |
Drug Categories | indoles |
Drug Categories | heterocyclic compounds, 2-ring |
Drug Categories | heterocyclic compounds, 1-ring |
Drug Categories | heterocyclic compounds |
Drug Categories | cytochrome p-450 cyp1a2 substrates |
Drug Categories | chemical actions and uses |
Drug Categories | biogenic monoamines |
Drug Categories | biogenic amines |
Drug Categories | azoles |
Drug Categories | antimigraine preparations |
Drug Categories | analgesics |
Drug Categories | amines |
Drug Groups | approved |
Drug Type | small molecule |
Name of the Ligand Species (if a Peptide) | Human |
FDA Approval | 1998 |
Drug Class | small molecule |
Drug Indications | Anti-migraine Agents |
agonist |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
agonist |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
agonist |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
Direct Interaction? | True |
agonist |
Trial Name | - |
Novel drug target | Established target |
Specific Action of the Ligand | Partial agonist |
agonist |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
n/a |
Specific Action of the Ligand | None |
Endogenous Drug? | True |
n/a |
n/a |
n/a |
n/a |
n/a |
n/a |
n/a |
n/a |
n/a |
n/a |
n/a |
n/a |
n/a |
RIZATRIPTAN | DrugBank Drug Name |
N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine | Drug Synonym |
N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine | Drug Synonym |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | amines |
RIZATRIPTAN | Primary Drug Name |
Year of Approval | 1998 |
Drug Class | anti-migraine agents |
FASLG | Gene Symbol (for Endogenous Peptides) |
FAS LIGAND | GuideToPharmacology Ligand Name |
178101771 | PubChem Drug SID |
Name of the Ligand Species (if a Peptide) | Human |
Drug Indications | Anti-migraine Agents |
Drug Class | small molecule |
FDA Approval | 1998 |
C1538 | NCI drug code |
C1538 | NCI drug code |
I06-2272 | Drug Synonym |
CID5078 | Drug Synonym |
DAP000220 | TTD Drug Id |
51086HBW8G | Drug Synonym |
RIZATRIPTAN | pubchem_primary_name |
5078 | PubChem CID |
RIZATRIPTAN | GuideToPharmacology Ligand Name |
135650905 | PubChem Drug SID |